Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 12/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915930 | 0.79 | HTR5A (0.43) | HTR5AGPR3BRPF1CREBBPIDO1 | |
| SCHEMBL2520126 | 0.79 | HTR5A (0.43) | HTR5AGPR3BRPF1CREBBPIDO1 | |
| SCHEMBL29915675 | 0.79 | HTR5A (0.43) | HTR5AGPR3 | |
| SCHEMBL2523848 | 0.79 | HTR5A (0.43) | HTR5AGPR3 | |
| Hydrochloric Acid SCHEMBL5711670 | 0.78 | HTR5A (0.42) | HTR5AGPR3 | |
| Hydrochloric Acid SCHEMBL5711485 | 0.78 | HTR5A (0.42) | HTR5AGPR3BRPF1CREBBPIDO1 | |
| SCHEMBL10061671 | 0.70 | OPRM1 (0.41) | — | |
| SCHEMBL1879473 | 0.68 | HTR5A (0.43) | HTR5ABRPF1CREBBPIDO1 | |
| SCHEMBL23563149 | 0.67 | GPR3 (0.60) | GPR3PRCP | |
| SCHEMBL13366003 | 0.66 | HTR5A (0.48) | HTR5ATSHRBRPF1CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | HTR5A 2844/4885GPR3 2354/4885PRCP 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.